Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of mouthguard use and jaw clenching on athletic strength.

General dentistry·2026

Same author

Rational design of synthetic proteins using a genome-scale CRISPR screen.

bioRxiv : the preprint server for biology·2026

Same author

Identification of target genes and regulatory networks for bone mineral density GWAS loci through systematic targeting and inhibition.

bioRxiv : the preprint server for biology·2026

Same author

Effectiveness of Artificial Intelligence Models for Detection of Vertical Root Fractures: A Systematic Review.

Journal of endodontics·2026

Same author

Influence of mouthguards on athletic balance: A scoping review.

Journal of the American Dental Association (1939)·2026

Same author

DYRK1A Expression and Thyroid Dysfunction in Subjects With Down Syndrome.

Clinical endocrinology·2026

Search research articles

Related Experiment Video

Updated: Sep 5, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Recurrent somatic mutations as predictors of immunotherapy response.

Zoran Z Gajic^1,2,3, Aditya Deshpande^1,4,5, Mateusz Legut^1,2,3

¹New York Genome Center, New York, NY, 10013, USA.

Nature Communications

|July 8, 2022

Summary

Identifying predictive biomarkers for immune checkpoint blockade (ICB) is crucial for cancer immunotherapy. Researchers developed the Cancer Immunotherapy Response CLassifiEr (CIRCLE) using mutation data, improving prediction accuracy over tumor mutational burden alone.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

Related Experiment Videos

Last Updated: Sep 5, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

Area of Science:

Oncology
Immunology
Genetics

Background:

Immune checkpoint blockade (ICB) offers a promising cancer treatment modality.
Variable patient responses to ICB highlight the need for predictive biomarkers.
Accurate prediction of ICB response is essential for optimizing patient outcomes.

Purpose of the Study:

To identify genes and pathways that predict response to ICB therapy.
To develop a novel classifier for predicting ICB treatment efficacy.
To improve upon existing methods for predicting cancer immunotherapy response.

Main Methods:

Analysis of six whole exome sequencing cohorts with matched clinical outcomes.
Identification of significantly mutated genes and pathways after covariate correction.
Development and validation of the Cancer Immunotherapy Response CLassifiEr (CIRCLE).

Main Results:

Identified BCLAF1, KRAS, BRAF, and TP53 mutations as predictors of ICB response.
Highlighted MAPK signaling, p53-associated, and immunomodulatory pathways as predictive.
CIRCLE demonstrated superior prediction accuracy compared to tumor mutational burden alone, with increased sensitivity and specificity.

Conclusions:

Recurrently mutated cancer genes can serve as robust biomarkers for ICB response.
The CIRCLE classifier offers improved prognostic capability for cancer immunotherapy.
This approach paves the way for enhanced personalized treatment strategies in oncology.